Foreign Drug Inspections Would Be Funded By Registration Fees In Draft U.S. Bill
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA inspections of overseas drug producers would be supported by annual registration fees under a legislative "discussion draft" being circulated by House Energy and Commerce Committee Chairman John Dingell, D-Mich.
You may also be interested in...
Baxter’s War Games: Post-Heparin, Scientists Consider Supply Chain Threats
Part of Baxter's response to its heparin contamination fiasco has been to bring its scientists together to imagine ways counterfeiters could infiltrate its supply chain and how they would be countered.
Baxter’s War Games: Post-Heparin, Scientists Consider Supply Chain Threats
Part of Baxter's response to its heparin contamination fiasco has been to bring its scientists together to imagine ways counterfeiters could infiltrate its supply chain and how they would be countered.
U.S. FDA’s Poor Performance ‘Invites Catastrophe’ – U.S. Congressional Committee On Heparin Investigation
The House Energy & Commerce Subcommittee on Oversight and Investigations simultaneously lauded and criticized U.S. FDA's handling of the heparin contaminant safety issue, which FDA now says was most likely the result of intentional actions